FDA Accepts Roche's Subsidiary Genentech's Application Of Crovalimab For The Treatment Of PNH, A Rare Life-Threatening Blood Condition
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted the application of Roche's subsidiary Genentech's drug, Crovalimab, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare life-threatening blood condition. This could potentially open a new revenue stream for Roche.
September 06, 2023 | 6:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's acceptance of Genentech's Crovalimab could potentially open a new revenue stream for Roche, positively impacting its stock.
The FDA's acceptance of the drug application is a positive development for Roche. If approved, it could lead to increased revenues from the sale of the drug, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The FDA's acceptance of Genentech's Crovalimab could potentially open a new revenue stream for Roche, positively impacting its stock.
The FDA's acceptance of the drug application is a positive development for Roche. If approved, it could lead to increased revenues from the sale of the drug, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100